RxDoctor Payments Data

Patrick Troy, MD

Pulmonary Disease · Hartford, CTNPI 1033255229

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $266,578 of the $385,379 with a category attached, or 69.2%. Boston Scientific accounts for 63.8% of it on its own, with 37 other manufacturers making up the rest. Among pulmonary disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$385,379in general payments, 2019–2025

Across 1,087 payments — averaging $354.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$246K
  • EKOS Corporation$45K
  • Baxter Healthcare$39K
  • AstraZeneca$30K
  • Jazz Pharmaceuticals Inc.$12K
  • Amgen$4K
  • plus $9K from 32 others

What the payments were for

  • Consulting fees$61,07916%
  • Speaking & faculty fees$266,57869%
  • Travel & lodging$31,6058%
  • Food & beverage$23,7216%
  • Education$2,3961%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$385,379 in reported general payments places this provider in the 95th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$155,755
Medicare patients
493
Services billed
1,132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter122$102,742
TezspireTezepelumab-Ekko12$53,834
Breo ElliptaFluticasone/Vilanterol34$13,566
Spiriva RespimatTiotropium Bromide17$9,963
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$8,753
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$3,045
Armodafinil18$1,315
Albuterol Sulfate HfaAlbuterol Sulfate51$790
Azelastine Hcl31$483
Montelukast Sodium26$361
Clonazepam13$246
Ipratropium Bromide15$202
Zolpidem Tartrate23$140
Prednisone20$101
Fluticasone Propionate15$99

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$3,028$125,061172 claims
AstraZenecaTezspire$30,028$53,83412 claims
Boehringer IngelheimSpiriva Respimat$559$9,96317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 255 pulmonary disease providers in Connecticut.

Other pulmonary disease in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →